Get the Stockscreener App
4.60
9.31%
0.41
Bioatla Inc stock is traded at $4.60, with a volume of 127.37K.
It is up +9.31% in the last 24 hours and up +37.54% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
See More
Previous Close:
$4.19
Open:
$4.5
24h Volume:
127.37K
Relative Volume:
2.71
Market Cap:
$7.63M
Revenue:
$2.00M
Net Income/Loss:
$-50.62M
P/E Ratio:
-0.11
EPS:
-41.8255
Net Cash Flow:
$-37.11M
1W Performance:
+19.58%
1M Performance:
+37.54%
6M Performance:
-78.72%
1Y Performance:
-75.64%
1-Day Range:
$4.24
$4.73
1-Week Range:
$3.77
$4.73
52-Week Range:
$3.12
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
4.60 | 6.87M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherMargin Compression Risk - dars.gov.et
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineMargin Guidance - newsline.com
BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Driven by Operational DisciplineEarnings Whisper Number - newsline.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces HeadwindsProfitability Factor - The Legal Advocate
BCAB Q4 2025 Earnings: EPS Surprise and Pipeline Focus Drive Positive SentimentEarnings Outlook Update - newsline.com
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95Schiff Line - The Legal Advocate
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentRevenue Surprise History - newsline.com
BCABBioAtla Inc Stock Price and Quote - Finviz
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
The real story behind BioAtla BCAB valuation 333 20260507Margin Improvement Report - newsline.com
BioAtla (BCAB) slashes R&D, flags going-concern risk amid cash crunch - Stock Titan
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Number of shareholders of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla (BCAB) Stock Analysis: +2.61% Gain — What to Watch 2026-05-14Continuation Pattern - newser.com
BCAB Q1'26 Earnings: EPS estimate is (10.00) USD - TradingView
TradingKey - TradingKey
The real story behind BioAtla (BCAB) valuation (-3.33%) 2026-05-07Quote Data - Newser
BCAB BioAtla delivers narrower than expected Q4 2025 loss, shares gain nearly two percent today.Social Trade Signals - newser.com
Why is BioAtla (BCAB) stock gaining attention recently | Q4 2025: Better Than ExpectedMarket Hype Signals - Newser
BioAtla, Inc. Executive Compensation, Governance, and Board Diversity Overview 2025 - Minichart
Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A - Stock Titan
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):